The Epidemiology of Tuberculosis in the United States

Joseph Burzynski; Neil W. Schluger

doi:10.1055/s-0028-1085701

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2008; 29(5): 492-498
DOI: 10.1055/s-0028-1085701

The Epidemiology of Tuberculosis in the United States

Joseph Burzynski¹ , Neil W. Schluger¹ ^, ²

¹Columbia University College of Physicians and Surgeons, New York, New York
²Columbia University Mailman School of Public Health, New York, New York

Abstract

ABSTRACT

Effective control of tuberculosis (TB) requires an understanding of the changing epidemiology of the disease. An understanding of the epidemiology is needed for public health departments to respond with appropriate program-planning decisions. Following a marked decline in the incidence of tuberculosis in the United States over several decades, the incidence escalated dramatically and peaked in 1992. The resurgence of TB reflected several factors, including deteriorating social conditions, dismantling of the public health infrastructure, dwindling support for tuberculosis clinics and services, the new epidemic of HIV/AIDS with highly susceptible individuals at risk, and immigration of individuals from countries with high rates of TB. Since 1992, there has been a substantial decline in new cases. The success in reducing the tuberculosis burden reflects several factors, including improved public health efforts, physician and patient education, infection control measures, and the use of directly observed therapy (DOT). By 2006, cases of TB in the United States had reached historic lows. Currently, a majority of cases of TB occur in foreign-born individuals, reflecting immigration from countries with high endemic rates of TB. Future efforts to curtail the incidence of TB will require vigilant public health efforts, improving education of patients and health care personnel, identifying mechanisms and routes of transmission, and assuring adequate treatment and prophylactic regimens among infected individuals.

KEYWORDS

Tuberculosis - epidemiology - United States - Mycobacterium tuberculosis - public health

Full Text

References

REFERENCES

1 Taylor Z, Nolan C M, Blumberg H M. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005; 54 1-81
2 Frieden T R, Lerner B H, Rutherford B R. Lessons from the 1800s: tuberculosis control in the new millennium. Lancet. 2000; 355 1088-1092
3 Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000; 161 1376-1395
4 Dubos R, Dubos J. The White Plague. Boston; Little, Brown 1952
5 Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis. 1991; 144 745-749
6 Sidel V W, Drucker E, Martin S C. The resurgence of tuberculosis in the united states: societal origins and societal responses. J Law Med Ethics. 1993; 21 303-316
7 Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993; 328 521-526
8 Gandhi N R, Moll A, Sturm A W et al.. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368 1575-1580
9 Kremer K, van Soolingen D, Frothingham R et al.. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol. 1999; 37 2607-2618
10 van Embden J D, van Soolingen D, Small P M, Hermans P W. Genetic markers for the epidemiology of tuberculosis. Res Microbiol. 1992; 143 385-391
11 Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med. 2001; 249 1-26
12 van Soolingen D, Hermans P W, de Haas P E, Soll D R, van Embden J D. Occurrence and stability of insertion sequences in mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991; 29 2578-2586
13 Daley C L, Small P M, Schecter G F et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992; 326 231-235
14 Small P M, Hopewell P C, Singh S P et al.. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med. 1994; 330 1703-1709
15 Alland D, Kalkut G E, Moss A R et al.. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med. 1994; 330 1710-1716
16 Geng E, Kreiswirth B, Burzynski J, Schluger N W. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA. 2005; 293 2740-2745
17 Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City—turning the tide. N Engl J Med. 1995; 333 229-233
18 CDC . Trends in tuberculosis incidence–United States, 2006. MMWR Morb Mortal Wkly Rep. 2007; 56 245-250
19 Trends in tuberculosis—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57 281-285
20 Muga R, Ferreros I, Langohr K et al.. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007; 21 2521-2527
21 Moh R, Danel C, Messou E et al.. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007; 21 2483-2491
22 Albalak R, O'Brien R J, Kammerer J S et al.. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993–2004. Arch Intern Med. 2007; 167 2443-2452
23 Zabana Y, Domenech E, San Roman A L et al.. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008; , May 1 [Epub ahead of print]
24 Leung C C, Lam T H, Chan W M et al.. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol. 2008; 167 1486-1494
25 Cain K P, Haley C A, Armstrong L R et al.. Tuberculosis among foreign-born persons in the united states: achieving tuberculosis elimination. Am J Respir Crit Care Med. 2007; 175 75-79
26 Geng E, Kreiswirth B, Driver C et al.. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002; 346 1453-1458
27 Walter N D, Jasmer R M, Grinsdale J, Kawamura L M, Hopewell P C, Nahid P. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis. 2008; 46 103-106
28 Dahle U R, Eldholm V, Winje B A, Mannsaker T, Heldal E. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med. 2007; 176 930-935
29 Brodie D, Lederer D J, Gallardo J S, Trivedi S H, Burzynski J N, Schluger N W. Use of an interferon-gamma release assay to diagnose latent tuberculosis infection in foreign-born patients. Chest. 2008; 133 869-874
30 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146 340-354
31 Andrews J R, Shah N S, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis. 2007; 196(Suppl 3) S482-S490
32 Wells C D, Cegielski J P, Nelson L J et al.. Hiv infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007; 196(Suppl 1) S86-S107
33 Matteelli A, Migliori G B, Cirillo D, Centis R, Girard E, Raviglion M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther. 2007; 5 857-871
34 Bai G H, Park Y K, Choi Y W et al.. Trend of anti-tuberculosis drug resistance in Korea, 1994–2004. Int J Tuberc Lung Dis. 2007; 11 571-576
35 Blondal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ. 2007; 85 387-390 discussion 391-384
36 Zignol M, Hosseini M S, Wright A et al.. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194 479-485
37 Yerokhin V V, Punga V V, Rybka L N. Tuberculosis in Russia and the problem of multiple drug resistance. Ann N Y Acad Sci. 2001; 953 133-137
38 Fujiwara P I, Cook S V, Rutherford C M et al.. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med. 1997; 157 531-536
39 Healthy People 2010. Washington, DC; Office of Health Promotion and Preventive Services, Department of Health and Human Services 2000
40 Schwartzman K, Oxlade O, Barr R G et al.. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 2005; 353 1008-1020
41 Khan K, Wang J, Hu W, Bierman A, Li Y, Gardam M. Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med. 2008; 177 455-460
42 Bennett D E, Courval J M, Onorato I et al.. Prevalence of tuberculosis infection in the United States population: the National Health and Nutrition Examination Survey, 1999–2000. Am J Respir Crit Care Med. 2008; 177 348-355
43 Bates M N, Khalakdina A, Pai M, Chang L, Lessa F, Smith K R. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med. 2007; 167 335-342

Neil W SchlugerM.D.

Columbia University Medical Center, PH-8 East, Rm. 101, 622 W. 168th St.

New York, NY 10032

Email: ns311@columbia.edu